Recently, the role of N-linked glycans in the process of ERAD (endoplasmic reticulum-associated degradation) of proteins has been widely recognized. In the present study, we attempted to delineate further the sequence of events leading from a fully glycosylated soluble protein to its deglycosylated form. Degradation intermediates of a truncated form of ribophorin I, namely RI 332 , which contains a single N-linked oligosaccharide and is a substrate for the ERAD/ubiquitin-proteasome pathway, were characterized in HeLa cells under conditions blocking proteasomal degradation. The action of a deoxymannojirimycin-and kifunensine-sensitive α1,2-mannosidase was shown here to be required for both further glycan processing and progression of RI 332 in the ERAD pathway. In a first step, the Man 8 isomer B, generated by ER mannosidase I, appears to be the major oligomannoside structure associated with RI 332 intermediates. Some other trimmed N-glycan species, in particular Glc 1 Man 7 GlcNAc 2 , were also found on the protein, indicating that several mannosidases might be implicated in the initial trimming of the oligomannoside. Secondly, another intermediate of degradation of RI 332 accumulated after proteasome inhibition. We demonstrated that this completely deglycosylated form arose from the action of an N-glycanase closely linked to the ER membrane. Indeed, the deglycosylated form of the protein remained membrane-associated, while being accessible from the cytoplasm to ubiquitinating enzymes and to added protease. Our results indicate that deglycosylation of a soluble ERAD substrate glycoprotein occurs in at least two distinct steps and is coupled with the retro-translocation of the protein preceding its proteasomal degradation.
INTRODUCTION
In recent years, the ER (endoplasmic reticulum) has been recognized as a quality-control compartment, where newly synthesized polypeptides delivered by co-and/or post-translational translocation undergo a sequence of biochemical modifications monitored by a number of chaperones, enzymes and folding factors [1] [2] [3] . In essence, only proteins that have attained a properly folded state are competent to leave the ER for further progression through the secretory pathway. Proteins that have remained partially folded or assembled and those with misfolded conformations are recognized as aberrant and, in most cases, are targeted for ERAD (ER-associated degradation). In this process, the proteins are retro-translocated to the cytoplasm and subjected to degradation by the ubiquitin-proteasome system [4, 5] . For glycoproteins, the N-linked oligosaccharides have been implicated in quality control and ERAD in various ways [2, [6] [7] [8] . One important feature of the N-glycan is to confer to glycoproteins the capacity for temporary and regulated retention in the ER, through transient binding of the monoglucosylated form of the N-glycan to the ER lectins calnexin and/or calreticulin. A cycle of binding to and release from these chaperones is determined by the sequential action of UDP-glucose-glycoprotein glucosyltransferase and glucosidase II, which adds and removes a terminal glucose from the oligomannose [2, 9, 10] . This mechanism is believed to support the folding of newly synthesized glycoproteins. Additionally, in the case where the protein does not acquire its native structure, the ER α1,2-mannosidase I has been proposed to act as a timer for the exit of the substrate glycoprotein from the calnexin cycle by producing a Man 8 oligomannoside [11] [12] [13] . This N-linked glycan structure is considered to be implicated in the binding to a Man 8 -specific ER lectin, an interaction that may play a role in the delivery of the glycoprotein to the degradative pathway, both in yeast and in mammals [14] [15] [16] [17] [18] .
This well-recognized role of ER mannosidase I in generating a Man 8 structure that functions as a signal for ERAD often relies on the observation that different ERAD substrates are stabilized in cells treated with specific α1,2-mannosidase inhibitors. However, in most cases, the precise N-glycan structures adopted by the glycoprotein to be degraded were not determined. Remarkably, such a Man 8 structure also occurs on properly folded glycoproteins that leave the ER, and other mannosidases from ER or post-ER compartments could account for ERAD pathways [19] [20] [21] [22] . For instance, the endomannosidase which cleaves the terminal mannose from the linear branch of the N-glycan only when it is glucosylated [19] could contribute to the release of incompletely folded glycoproteins from the calnexin cycle. Specific inhibitors of α1,2-mannosidases could inactivate enzymes with different fine specificities such as the ER mannosidases I and II and the Golgi mannosidase I. Accordingly, for the stabilization of the H2a and H2b subunits of the asialoglycoprotein receptor by α1,2-mannosidase inhibitors, it has been proposed that a Man 6 GlcNAc 2 structure could serve as a degradation signal [20] . ER mannosidase II has also been described to act in the ERAD of an α1-antitrypsin variant, but through a proteasome-independent pathway [21] . Finally, our previous work using a glycosylationdefective cell line that synthesizes a truncated N-glycan lacking the mannose linkage specifically recognized by the ER mannosidase I showed stabilization of an ERAD substrate in the presence of α1,2-mannosidase inhibitors. We then developed a procedure that allowed us to describe, for the first time, the composition of the N-glycan associated with a glycoprotein during its degradation. This analysis revealed the implication of mannosidases with specificities similar to those of the Golgi mannosidase in this glycosylation-defective cell line [22] .
In view of these different observations, it was of importance to clarify the involvement of different enzymes implicated in Nglycan processing during ERAD of a glycoprotein in cells with a wild-type glycosylation phenotype. Therefore in the present study, we analysed in HeLa cells the N-glycan structures associated with degradation intermediates of a model substrate, RI 332 , which contains one N-linked glycan. RI 332 is a soluble truncated form of the rough ER-specific type I transmembrane glycoprotein RI (ribophorin I) which is rapidly degraded in CHO (Chinesehamster ovary) and HeLa cells by the classical ERAD pathway dependent on the ubiquitin-proteasome system [23, 24] . In addition, our previous results obtained with a temperature-sensitive CHO-cell mutant deficient in ubiquitination have suggested that processing intermediates produced during RI 332 degradation could originate in the lumen of the ER [23] . We show here by electrophoretic analysis that, when proteasomal degradation is inhibited in HeLa cells, two distinct intermediates of RI 332 accumulated in comparable amounts, one being glycosylated and the other unglycosylated. N-glycan analysis revealed that the glycosylated intermediate contains the Man 8 isomer B structure, expected to be formed by the action of the ER α1,2-mannosidase I. In addition, significant levels of other trimmed N-glycan species were also detected that might be generated by other mannosidases. We also demonstrate that the second intermediate in the degradation pathway that corresponds to a deglycosylated form of the protein was produced by the complete removal of the N-linked glycan, thus establishing the role of an N-glycanase activity in this process.
EXPERIMENTAL

Reagents
The pQE-30 His 6 -tag expression vector, the Escherichia coli strain M15 [pREP4] for bacterial expression of His 6 -tagged proteins and Ni-NTA (Ni 2+ -nitrilotriacetate) Sepharose CL-6B beads were from Qiagen (Hilden, Germany). The T/A cloning vector pCR2.1 was purchased from Invitrogen (Groningen, The Netherlands). Oligonucleotides were from VBC Genomics (Vienna, Austria). Minimal essential medium, methionine-free RPMI 1640 and other cell culture reagents were obtained from Gibco BRL/Invitrogen Life Technologies (Paisley, Renfrewshire, Scotland, U.K.). 3 Hance solution were purchased from NEN TM Life Science Products (Boston, MA, U.S.A.). Ampholyte solutions were from Fluka (Buchs, Switzerland). X-Omat Blue XB-1 and BioMax MR X-ray films were purchased from Eastman Kodak (Rochester, NY, U.S.A.).
Antibodies
To prepare the rabbit anti-RI-lum antiserum, the cDNA corresponding to the luminal domain of mature rat RI was amplified by a standard PCR using the pWS-RI construct [24] cut with SacI as template and the primers AAACGGATCCTCTTCG-GAGGCTCCGCCGCTGG and AGGGGGTACCAGGCTCCT-GCAGCATGAGCACC. At the same time, BamHI and KpnI restriction sites were introduced so as to facilitate the cloning of the DNA fragment obtained, after a T/A cloning step utilizing the pCR2.1 vector, into the pQE-30 vector, using the BamHI and KpnI sites. The resulting polypeptide that contains a His 6 tag at its Cterminus was produced in E. coli M15 [pREP4] cells and purified by affinity chromatography on Ni-NTA Sepharose CL-6B beads under denaturing conditions (8 M urea). The purified polypeptide was used to immunize a rabbit as described in [22] .
The anti-RI-lum antibody works on SDS-denatured cell extracts under stringent conditions (0.6 % SDS and 1 % Triton X-100) [23] . The polyclonal rabbit anti-RI-LB antibody was described previously [22] .
Cell lines
The H3-2 and H3*-8 clones were obtained by transfecting HeLa cells with the cDNAs encoding the glycosylated RI 332 and the non-glycosylated RI 332 -Thr soluble variants of RI respectively as already described [24] . HeLa transfectants were grown in 5 % CO 2 at 37
• C and in minimal essential medium supplemented with 7 % (v/v) fetal calf serum.
Treatment of cells with drugs, cell labelling, immunoprecipitations and sequential precipitations
The transfected HeLa-RI 332 (H3-2) and HeLa-RI 332 -Thr (H3*-8) cells were plated at a density of 7 × 10 5 in a 35 mm dish and grown overnight. Cells were preincubated at 37
• C with 1 mM CST, 2 µg/ml Kif, 2 mM dMJ or 50 µM ZLLL for 1 h in complete medium and subsequently for 30 min in methionineand serum-free medium. Then the cells were pulse-labelled for 30 min with 500 µCi/ml of Tran 35 For immunoprecipitations with the anti-RI-lum antibody, the cells were lysed with 2 % (w/v) SDS, and the lysates were processed for immunoprecipitation under stringent conditions [0.6 % SDS and 1 % (v/v) Triton X-100] [23] . Alternatively, the cells were lysed with 1 % Triton X-100 in NET buffer (150 mM NaCl/ 50 mM Tris/HCl, pH 7.4/5 mM EDTA), supplemented with protease inhibitors (1.7 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml L-leucyl-L-leucyl-L-leucine and 5 mM PMSF), which was subsequently adjusted to 0.6 % SDS. Specific immunoprecipitations were performed overnight with 40 µl of Protein A-Sepharose and 5 µl of anti-RI-lum antiserum. After three washes with SDS wash buffer (95 mM NaCl/25 mM Tris/HCl, pH 7.4/3 mM EDTA/1.25 % Triton X-100/0.2 % SDS/protease inhibitors as above) and two with PBS, the immunoprecipitates were eluted with reducing sample buffer containing 3 % (v/v) 2-mercaptoethanol. Where indicated, immunoprecipitates were treated with endo H as described previously [25] . For treatment with PNGase F, immunoprecipitates were washed with deionized water and incubated with 1 % (v/v) Nonidet P40, 50 mM sodium phosphate (pH 7.5) and 3 µl of PNGase F at 37
• C for 4 h. Samples were analysed by SDS/PAGE (10 % gels), followed by fluorography.
For sequential precipitations with ConA lectin and anti-RI antibodies, the cell lysates obtained from cells treated with 1 % Triton X-100 in NET buffer, were initially incubated with 40 µl of ConA-Sepharose beads overnight. Subsequently, adsorbed proteins were released by boiling the beads twice in 150 µl of SDS lysis buffer (95 mM NaCl/25 mM Tris/HCl, pH 7.4/3 mM EDTA/1 % SDS/protease inhibitors) and diluted with 1 ml SDS wash buffer. The following immunoprecipitations with anti-RIlum were performed as above.
Cell fractionation, protease protection and ubiquitination analysis of ConA-separated material Analyses of cell fractions, protease protection using trypsin and ubiquitination were performed as described previously [23] .
Briefly, H3-2 cells labelled with Tran 35 S-label radioactive
Cys amino acid mixture treated with or without ZLLL were lysed by Dounce homogenization in iso-osmotic buffer. Membrane and soluble fractions were separated by ultracentrifugation at 100 000 g and then RI 332 was immunoprecipitated with anti-RI-lum antiserum and processed for SDS/PAGE analysis. Samples tested for protease protection were incubated with 10 µg/ml trypsin for 30 min at 30
• C; then protease inhibitors were added before immunoprecipitation. Ubiquitination of RI 332 was evaluated on cell lysates prepared in the presence of 0.2 % SDS and 5 mM NEM. Ubiquitinated material was also analysed after separation of glycosylated and non-glycosylated RI 332 by selective adsorption on ConA. Samples were then subjected to immunoprecipitations using anti-RI-lum antiserum, all in the presence of NEM, and analysed by SDS/PAGE and fluorography.
Isoelectric focusing (IEF)
For IEF analyses, immunoprecipitates were additionally washed twice with deionized water and taken up in 20 µl IEF sample buffer (9.5 M urea/2 % Triton X-100/0.8 % ampholytes, pH 3-10/5 % 2-mercaptoethanol). IEF gel electrophoresis under denaturing conditions was performed in slab gels [9.2 M urea/2 % Triton X-100/4 % (w/v) acrylamide/0.22 % bisacrylamide/ 4 % (v/v) ampholytes, pH 5-7/1 % ampholytes, pH 3-10/0.02 % ammonium persulphate/0.1 % N,N,N ,N -tetramethylethylenediamine] with 20 mM H 3 PO 4 as anode buffer. To all wells of the gel, 5 µl of overlay buffer (IEF sample buffer, diluted 1:3 and supplemented with 0.01 % Bromophenol Blue) was added and then 20 mM NaOH, which was also used as a cathode buffer. After the separation of the proteins at 10 mA for 14 h, the gels were fixed [30 % (v/v) methanol and 10 % (v/v) acetic acid] for 30 min, soaked in En 3 Hance solution for 10 min, washed with water for 10 min, dried and used for fluorography.
HPLC analysis of oligosaccharide structures
Procedures to prepare oligomannosides bound to total glycoproteins [26] or to a soluble variant of RI during its degradation [22] have already been described. In the present study, approx.
10
7 H3-2 cells starved for 30 min in a medium with low glucose concentration (0.5 mM) were thereafter metabolically labelled with 100 µCi of [2- 3 H]D-mannose for 45 min in glucose-free medium. After a 10 min chase in complete medium, total proteins were extracted with organic solvent as described by Kmiécik et al. [27] . N-glycans were released from protein by PNGase F, and then analysed by HPLC on an ASAHIPAK-NH2-P-50 column (Asahi, Kawasaki-ku, Japan) after elution in an acetonitrile gradient at a flow rate of 1 ml/min and monitored with a Flo-one β detector (Flotec, France).
To determine the composition of the N-glycans specifically associated with RI 332 , mannose-labelled glycoproteins were purified on Protein A-Sepharose beads coupled with anti-RI-LB antiserum. N-glycans were released directly from such purified RI 332 by treating the immunoprecipitated sample with PNGase F before HPLC analysis, as described in [22] . To study oligomannosides bound to RI 332 shortly after synthesis, Triton X-100 extracts were prepared from H3-2 cells labelled in the same way as described for total glycoproteins, except that 300 µCi of [2- 3 H]D-mannose was used. To study the N-glycan structures linked to RI 332 during its degradation, H3-2 cells were pretreated for 1 h with 40 µM ZLL-Nva proteasome inhibitor and the drug was maintained in each subsequent step, namely 30 min starvation, 45 min mannose labelling and the 4 h chase. Under these conditions, intermediates of degradation of RI 332 are known to accumulate. HPLC analysis of N-glycans released from RI 332 was then performed as described above.
Oligomannoside derivatization and HPLC analysis to determine Man 8 isomer
The major N-glycan species associated with RI 332 during its degradation were separated and purified by TLC. N-glycans were prepared from RI 332 immunoprecipitates of extracts from radiolabelled H3-2 cells treated and chased for 4 h with ZLLNva as described above for HPLC analysis. The cell lysate was precleared with Protein A-Sepharose beads coupled with nonimmune serum before specific immunoprecipitation with anti-RI-LB antiserum. The oligomannosides were released by endo H treatment of total proteins or of immunoprecipitated RI 332 , and then analysed by TLC. Samples were loaded on to a silicacoated layer and separated in n-propanol/acetic acid/water (3:3:2) solvent for 24 h before visualization by fluorography as described previously [28] .
The material corresponding to the Man 8 GlcNAc 1 spot was recovered from the TLC plate by water extraction. These oligomannosides were derivatized with 2-aminopyridine as described by Hase et al. [29] , and then desalted on a Biogel-P2 column. The derivatized oligosaccharides and standards (5 × 10 3 -10 4 c.p.m.) were injected on to a Hypersil ODS2 column (Supelco, Bellefonte, PA, U.S.A.; 250 mm × 4.5 mm) for analysis by HPLC. The column was eluted isocratically with 5 mM ammonium acetate (pH 4.0) at a flow rate of 0.5 ml/min using a Waters solvent delivery 600 system coupled with a Packard 150 TR flow scintillation analyzer. The isomers were identified by comparison with the elution time of known standardized material.
RESULTS
Degradation of the truncated RI 332 is mannosidase and proteasome dependent in HeLa cells
To study the relationships between N-glycosylation and glycoprotein degradation, we used as a model the truncated RI variant, RI 332 , an ERAD substrate that requires the ubiquitin-proteasome . Cells were lysed with SDS-containing buffer and processed for immunoprecipitation with the anti-RI-lum antiserum. The immunoprecipitates were analysed by SDS/PAGE (10 % gel) followed by fluorography. RI 332 ,Glc indicates a slower migrating form of RI 332 , which is generated in the presence of CST and is expected to bear three glucose residues.
system for its degradation [22] [23] [24] . Intermediates in the degradation pathway were characterized in the [
35 S]Met/Cyslabelled H3-2 clone, a HeLa cell transformant expressing RI 332 that was treated with the proteasome inhibitor ZLLL and/or inhibitors of N-glycan processing. Anti-RI immunoprecipitates were then analysed by SDS/PAGE (Figure 1 ). RI 332 is rapidly degraded in untreated cells with a half-life of approx. 1 h, as described previously [23] , and is detected as a unique band with an apparent molecular mass of approx. 40 kDa after 10 min chase ( Figure 1, lane a) . In contrast, two intermediates of degradation, RI 332 i 1 Next, to explore the requirement of an α1,2-mannosidase activity for ERAD of RI 332 , H3-2 cells were treated with two specific α1,2-mannosidase inhibitors, dMJ and Kif, for 3 h. The inhibition of α1,2-mannosidase activity resulted in the stabilization of RI 332 (Figure 1, lanes c and d) , consistent with earlier observations [24] . Interestingly, the formation of the faster migrating RI 332 i 2 intermediate, detected only in the presence of proteasome inhibitors, was essentially prevented when the cells were treated with either dMJ or Kif in addition to ZLLL (lanes g and h). These results demonstrate that an α1,2-mannosidase activity is a prerequisite for the processing on RI 332 , so as to generate the intermediate RI 332 i 2 .
These findings together with the prevailing view that a Man 8 structure of the N-linked oligosaccharide is critical on glycoproteins destined for ERAD [11] [12] [13] 30 ,31] prompted us to analyse the N-glycan structures present on RI 332 . To understand better the processing of the N-glycan associated with the intermediates of degradation of RI 332 accumulating in H3-2 cells in the presence of proteasome inhibitors (ZLL-Nva), the oligomannoside composition was determined by HPLC. After mannose labelling, oligomannosides were released by PNGase F treatment, either from newly synthesized total glycoproteins or from specifically immunoprecipitated RI 332 at 10 min chase, and then compared with the N-glycans accumulating on RI 332 when degradation is blocked for a 4 h chase in the presence of ZLLNva (Figure 2A ). Whereas two RI 332 degradation intermediates accumulated in equal amounts, as seen on SDS/PAGE (Figure 1 , lane e) in H3-2 cells treated with ZLLL, only one prevalent N-glycan moiety (and not two species in equal amounts) eluting as a Man 8 derivative, was detected by HPLC (Figure 2A, black bars) . In comparison, the major N-glycan species associated with the newly synthesized proteins at 10 min chase (either total glycoproteins or RI 332 ; Figure 2 (A), white and grey bars respectively) were Man 9 GlcNAc 2 moieties. These results show that the RI 332 i 1 intermediate observed after 35 S-labelling, in the presence of proteasome inhibitors, contains mainly the Man 8 derivative, whereas the lower RI 332 i 2 intermediate presumably does not possess N-glycans.
In addition to the accumulation of Man 8 derivatives accounting for 58 % of all the oligomannoside species linked to RI 332 degradation intermediates, our HPLC analysis also revealed, even after 10 min chase, the presence of significant amounts of shorter N-glycans that are not detected on total glycoproteins (Figure 2A , cf. grey and white bars). The quantity of these trimmed N-glycan structures slightly increased on RI 332 accumulating in H3-2 cells chased for 4 h in the presence of the proteasome inhibitor and reached a level of 12 % for Man 7 , 12% for Man 6 and 7 % for Man 5 GlcNAc 2 (black bars).
The Man 8 structure found associated with proteins during their degradation is considered to be derived from the action of the ER α1,2-mannosidase I [11] [12] [13] . The present finding of trimmed oligomannoside structures (Man 7 to Man 5 ) on RI 332 during its degradation ( Figure 2A ) and our previous observations in a glycosylation-defective cell line [22] , point to the possible role of other α1,2-mannosidase activities in this process. According to the different specificities of α1,2-mannosidases described so far, three Man 8 isomers could indeed occur. The ER mannosidase I that cleaves the middle branched terminal mannose produces an isomer B of Man 8 , whereas the ER mannosidase II specific for the terminal mannose of the α1,6-branched antennae generates an isomer C [32] . Also, the endomannosidase specific for the terminal α1,2-mannose linkage of the linear part of the high mannose structure, when it is glucosylated, could lead to the formation of Man 8 isomer A [19] . Golgi mannosidase I was also reported to have a high affinity for this terminal mannose [33, 34] . Therefore we next determined the isomeric structure of the major oligomannoside moiety associated with RI 332 degradation intermediates obtained after 4 h of chase in the presence of the proteasome inhibitor. For isomer determination, the Man 8 -containing structures were extracted from TLC plates (see Figure 2B ), derivatized with 2-aminopyridine, and then analysed by reversedphase HPLC (see Figure 2C ). TLC analysis of endo H-released glycans revealed that the oligosaccharide material corresponding to the migration profile of standard Man 8 GlcNAc 1 did not appear homogeneous, suggesting the presence of different Man 8 isomers or glucosylated Man 7 species. Radioactive material migrating at the level of Man 8 (indicated by a bar in Figure 2B, lane 3) was eluted from the TLC plate and derivatized. As shown in Figure 2B, lane 3) .
Altogether, these observations add to the complexity of the N-glycan processing relating to glycoprotein degradation of a particular ERAD substrate, which may involve the participation of different mannosidases.
The lower intermediate of RI 332 does not contain mannose and is the product of an N-glycanase activity
We were then interested in elucidating the nature of the faster migrating intermediate, RI 332 i 2 , only observed after proteasome By contrast, PNGase F treatment of RI 332 samples from both ZLLL-treated and -untreated cells, led to a unique band harbouring the same electrophoretic mobility when compared with RI 332 i 2 . This observation led us to speculate that RI 332 i 2 could be generated by the action of an N-glycanase-like activity. Such an enzyme is known to cleave the N-linked glycan from the asparagine residue to which it is attached and by doing so generate an aspartic acid. This modification changes the pI of the protein. For the mature RI 332 protein, we obtained a pI of 6.07. For the corresponding form in which one asparagine residue was converted into aspartic acid, a pI of 5.94 is expected. IEF experiments were therefore performed using anti-RI immunoprecipitates prepared from different H3-2 cell lysates treated with or without with PNGase F (Figure 5 ). An additional band corresponding to a more acidic protein was observed only in cells treated with ZLLL ( Figure 5A, lane b) . This band migrates more towards the anode when compared with the other form also recovered from untreated cells (lanes a and b) . The nonglycosylated variant of RI 332 , where the asparagine residue of the N-glycosylation sequon had been replaced by a threonine (RI 332 -Thr) and expressed in HeLa cells (H3 * -8), was used as control. As Finally, we investigated the intracellular localization of the Nglycanase activity detected during RI 332 degradation. A cell fractionation assay revealed that both the glycosylated intermediates RI 332 i 1 and the deglycosylated product RI 332 i 2 in ZLLLtreated H3-2 cells (Figure 6A, lanes c and d) , as well as the glycosylated form of RI 332 in untreated cells (lanes a and b) , are associated almost exclusively with microsomal membranes. This is in agreement with similar results previously obtained in the mutant ts20 CHO cell line [23] . Figure 6(B) indicates that, after digestion of the microsomes with trypsin, most of the deglycosylated intermediate, RI 332 i 2 , is sensitive to the protease, whereas the glycosylated form remains resistant (lanes a and b) . Furthermore, a ConA separation of N-glycosylated proteins from those devoid of oligomannosides was performed. Total or ConAseparated proteins from the microsomal fraction were precipitated with anti-RI antibodies in the presence of NEM to prevent deubiquitination of proteins. Under these conditions, a number of high-molecular-mass bands were visible in the sample prepared from total microsomes, typical for poly-ubiquitinated proteins ( Figure 6C, lane a) . In this sample, the band corresponding to glycosylated RI 332 is easily discernable. In contrast, the deglycosylated RI 332 i 2 form is almost undetectable suggesting that this form may be ubiquitinated to a large extent and shifted to highmolecular-mass bands. This is confirmed by results from the ConA fractionation. Indeed, the high-molecular-mass forms are present only in the supernatant of the ConA-treated sample, enriched in deglycosylated RI 332 i 2 (lane b), but not in the pellet from the ConA-retained material, where only the glycosylated form of the protein is found (lane c). This demonstrates that only the deglycosylated form of RI 332 is ubiquitinated. Endogenous, glycosylated RI also appears to be enriched in the ConA-retained fraction.
In summary, these results provide evidence that deglycosylation of RI 332 occurs when the protein is still associated with the microsomes. However, it is not clear whether the implicated Nglycanase exerts its activity on the luminal or cytoplasmic face of the ER.
DISCUSSION
The importance of N-linked glycan structures, in particular the isomer B of Man 8 GlcNAc 2 , as intermediates and regulatory devices in the pathway of ERAD has been widely recognized [2, 3, 9, 35, 36] . However, the precise N-glycan structure targeting proteins to ERAD and the mechanism leading to dislocation of glycoproteins from the ER to the cytosol for proteasomal degradation, remain open questions. In an attempt to understand better the requirement for N-glycans in the process of glycoprotein degradation, we analysed the processing of the single Nlinked oligosaccharide on the ERAD substrate RI 332 , a soluble truncated form of RI, during the course of its disposal. Normally, endogenous full-length RI, a long-lived ER-resident glycoprotein, possesses predominantly a fully mannosylated oligosaccharide chain. In fact, pulse-chase studies showed that Man 9 GlcNAc 2 is the major structure on RI up until 7 h of chase [25] . In the present study, we show that an N-glycan corresponding to Man 8 GlcNAc 2 isomer B, but interestingly also other shorter species, Glc 1 Man 7 GlcNAc 2 Man 6 GlcNAc 2 and Man 5 GlcNAc 2 , are associated with RI 332 during its degradation. Then, in a second step, deglycosylation of the RI 332 ERAD substrate by an N-glycanase occurs in a mannosidase-dependent fashion and is tightly coupled with retro-translocation of the glycoprotein, preceding proteasomal degradation.
The first main conclusion drawn from our findings is the requirement of the action of a dMJ-and Kif-sensitive mannosidase for the degradation of RI 332 . This is in agreement with previous observations by others and by us [12, 13, 24] . Interestingly, we found that both complete deglycosylation and degradation of RI 332 do not occur if this mannosidase activity is compromised.
Based on genetic evidence in yeast [11, 16, 37] and on numerous studies with inhibitors in mammalian cells [6, 12, 13, 24, 38] , it was concluded that ER mannosidase I is the central player in this process. However, most of the conclusions on the role of ER-mannosidase I were drawn from indirect observations such that different ERAD substrates accumulated in the presence of specific α1,2-mannosidase inhibitors. It is probable that degradative pathways involving other α1,2-mannosidases may also contribute to generating different N-glycan structures [21] . Supporting this view, our previous determination of the N-glycan structures associated with an HA (haemagglutinin)-epitopetagged form of RI 332 (RI 332 -3HA) during its degradation in the glycosylation-defective CHO cell line, MadIA214, has demonstrated a requirement of an α1,2-mannosidase activity different from that of the ER-mannosidase I [22] . Indeed, in this cell line, truncated Man 5 GlcNAc 2 are added to proteins, but this oligomannoside is not expected to be a substrate for the highly specific ER mannosidase I [33] . The simple N-glycan structure found in the glycosylation mutant cell line allowed us to speculate that the monoglucosylated N-linked Man 5 GlcNAc 2 accumulating in the presence of mannosidase inhibitors could prolong retention of the improperly folded glycoprotein within the calnexin cycle. The trimmed Man 4 GlcNAc 2 and Man 3 GlcNAc 2 intermediates, detected when proteasomes are inhibited, could then arise by the action of a Golgi mannosidase after cycling of RI 332 -3HA through the ER and cis-Golgi. Our hypothesis was that this activity would impair reglucosylation of the ERAD substrate and consequently its calnexin binding, thus favouring disposal of the glycoprotein [22] .
This observation of a role for the mannosidase activity different from the ER-mannosidase I activity in ERAD could still be specific for the MadIA214 mutant cell line. Therefore in the present study, we questioned whether other mannosidases could also act on an ERAD substrate in cells synthesizing a complete high mannose core (Glc 3 Man 9 GlcNAc 2 ). The mannosidase activity revealed in mutant CHO cells could produce the A isomer or related structures of Man 8 GlcNAc 2 if operating in wild-type cells. Various ER and Golgi mannosidases, for which a role has yet to be ascribed, may actually perform different functions in processing and degradation of glycoproteins [20, 36, 39] . This could also be achieved by the endomannosidase detected in the cisGolgi of certain cell types, which produces an isomer A of Man 8 GlcNAc 2 from monoglucosylated Man 9 GlcNAc 2 [19] . In addition, results obtained in vitro, which remain to be confirmed in vivo, suggest that at very high concentrations the specificity of the ER mannosidase I could be broader than described previously [40] . Here we analysed the structures of the N-linked oligosaccharides recovered from the ERAD substrate RI 332 expressed in HeLa cells after a proteasomal block, which comprise intermediates in the degradation pathway that accumulate under these conditions. The finding that most of the Man 8 GlcNAc 2 corresponds to the isomer B is consistent with the earlier proposal that ER mannosidase I is the predominant mannosidase acting on glycoprotein ERAD substrates. Moreover, since in our analysis the N-linked Glc 1 Man 7 GlcNAc 2 was also observed on RI 332 , it appears that this glycoprotein is also a substrate for other mannosidases, such as ER mannosidase II. Other N-glycans, including Man 6 GlcNAc 2 and Man 5 GlcNAc 2 , were additionally found associated with purified RI 332 in the course of its degradation. The occurrence of these latter structures can be explained by the action of α1,2-mannosidases similar to those observed in MadIA214 glycosylation mutant cells, possibly the Golgi mannosidase I or ER-Man 9 mannosidase or the endomannosidase which has been shown to be expressed in several human cell lines [19] . Thus it is remarkable that for one given ERAD substrate several mannosidases might be involved. From previous work, the degradation of RI 332 in HeLa cells appears to be biphasic, with a first step depending on calnexin interaction; accordingly, the non-glycosylated variant of RI 332 is more rapidly degraded [23] . The presence of N-linked Glc 1 Man 7 GlcNAc 2 , and of monoglucosylated Man 9 GlcNAc 2 and Man 8 GlcNAc 2 derivatives, although in smaller amounts, strengthened the role of calnexin in the degradation pathway. This is also in agreement with the observation that inhibiting calnexin binding by CST treatment accelerates the degradation of RI 332 [24] . In contrast, mannosidase inhibitors stabilized the glycoprotein, possibly favouring the reglucosylation of the Nglycan, thus causing its prolonged retention in the calnexin cycle.
Altogether, these results indicate that the RI 332 ERAD substrate is trimmed in the ER by both the ER mannosidases I and II, leading to N-linked Man 9 GlcNAc 2 , Man 8 GlcNAc 2 and Man 7 GlcNAc 2 . All of them can be reglucosylated and retained by calnexin. Therefore Glc 1 Man 7 GlcNAc 2 observed in the presence of proteasome inhibitors appears to be a critical structure, still allowing calnexin binding, but from which further trimming of an α1,2-mannose residue could be the signal for proteasomal degradation. Indeed, the smaller N-glycans, Man 6 GlcNAc 2 and Man 5 GlcNAc 2 generated by a mannosidase capable of cleaving the terminal mannose residue that serves as a substrate for reglucosylation are also observed. We propose that these structures are probably those required for targeting of glycoproteins to degradation by the proteasome as supported by our previous observations on RI 332 -3HA intermediates of degradation in the MadIA214 glycosylation-defective cell line. Such a scenario is consistent with the results from the literature pointing to the role of a dMJ-and Kif-sensitive α1,2-mannosidase, however different from ER mannosidase I. Therefore, the postulated lectin EDEM, specific for the B isomer of Man 8 GlcNAc 2 N-glycans and required for the disposal of the ERAD substrate, will be required to have a broader specificity to accommodate our present findings. After submission of this paper, a report by Lederkremer and co-workers [41] appeared, which supports our observation of highly trimmed N-glycans (Man 6−5 GlcNAc 2 ). Another possibility to explain our results could be that two pathways depending on two different α,1,2-mannosidases participated in the disposal of RI 332 : one would involve the B isomer of Man 8 GlcNAc 2 and would depend on EDEM and the other would involve the Man 6 GlcNAc 2 structure resulting in the exit of the substrate protein from the calnexin cycle and would be independent of the EDEM lectin. This study also indicates that the degradation process is more complex than initially anticipated and that the use of specific inhibitors and electrophoretic analyses are insufficient to identify N-glycan structures that are involved in ERAD.
Our results also show that the final step in the deglycosylation process of RI 332 during its degradation pathway is effected by an N-glycanase. This activity cleaves the complete N-glycan from the glycoprotein and converts the asparagine residue, to which it was attached, into aspartic acid [42, 43] . At present, it is not clear whether the N-glycanase action requires previous trimming of the N-linked oligosaccharide by an α1,2-mannosidase, or whether trimming needs to occur for progression in the pathway before the N-glycanase step, e.g. to allow recognition by a sensing and/or conveying molecule, such as a specific ER lectin [11, [14] [15] [16] [17] [18] . In this context, our observation that CST treatment permits the fully deglycosylated intermediate to be produced may indicate that avoiding calnexin binding favours mannosidase processing for further progression in the ERAD pathway. These results and the observation that inhibitors of α1,2-mannosidases block not only degradation but also deglycosylation processes are compatible with our hypothesis on the role of a mannose-trimmed structure that cannot be reglucosylated as an intermediate of degradation.
Nevertheless, the membrane topology and the mechanism of glycoprotein dislocation are not fully understood. The occurrence and properties of the deglycosylated form of RI 332 raised the question as to where it is produced. Our previous studies with CHO cells [23] and the present study using HeLa cell transformants are compatible with a luminal cleavage of the N-glycan. An N-glycanase activity in the lumen of the ER has indeed been reported [35, 44, 45] . Alternatively, it is also conceivable that the N-linked oligosaccharide of RI 332 is cleaved by a cytoplasmic PNGase, after the glycoprotein engages with the translocation channel. A cytoplasmic PNGase was described in yeast [46] and in mammals [43] based on cloning of the genes and characterization of the corresponding gene products. Interestingly, a role for Nglycanase in the cytosolic turnover of glycoproteins has very recently been proposed in yeast [47] and in mammals [48] . In such a scenario, the N-glycan of RI 332 might be exposed at the cytoplasmic side of the ER membrane, becoming accessible to the cytoplasmic PNGase. This might also explain why the deglycosylated intermediate RI 332 appears to be only loosely associated with the ER membrane, as it is largely sensitive to exogenously added protease and may readily become a substrate for ubiquitination.
Although several ERAD substrates have been demonstrated to proceed through a deglycosylated intermediate [49] [50] [51] [52] , this is not always the case. It is noteworthy that after inhibition of the proteasome, we were unable to observe the deglycosylated intermediate of the RI 332 -3HA-tagged version of RI 332 ( [22] and our unpublished results). The N-linked glycosylation site is located only 57 amino acids from the C-terminus of the RI 332 protein, whereas RI 332 -3HA contains an additional 35-aminoacid-long peptide at its C-terminus corresponding to the three repeats of an HA-epitope. In this context, it is interesting to note that a PNGase from hen oviduct was described to deglycosylate specifically only the more C-terminally located N-glycan (Asn 311 ) out of two (Asn 292 , Asn 311 ) on ovalbumin, a secreted protein of 385 amino acids [53] . These observations might indicate that the N-linked glycan has to be at a certain distance from the C-terminus to be excised by a cytoplasmic PNGase. However, at no instance were the orientation and the folding state of the glycoprotein during dislocation elucidated and models have been proposed [54, 55] . Therefore it cannot be excluded that differences in the folding between the tagged and the untagged protein could affect the accessibility to the PNGase, which then could not be easily revealed in the presence of a proteasome inhibitor. Further experiments will be required to distinguish between these possibilities.
